Choose the brand aligned with your industry so we can best serve your needs.
Count on high-quality Abbott™ diagnostic products and services for reliable and actionable information to help providers improve patient care. Through the use of innovative technologies, we not only transform diagnostic products, but also expand into new platforms and solutions, resulting in better clinical and economic outcomes.
Highly accurate, molecular results in less than 15 minutes. Rapid diagnosis of influenza can lead to reduced hospital stays, secondary complications, and cost of hospital care.1,2
Abbott™ Determine™ HIV-1/2 Ag/Ab Combo is a fourth-generation test that has the ability to detect HIV earlier than second- and third-generation antibody-only tests.2 It can detect infection three weeks after it occurs as opposed to other tests that can only detect it after three months. This enables healthcare providers to diagnose HIV infection earlier, allowing individuals to seek medical care sooner.
Identifying HIV infection early, during the most infectious stage, offers significant benefits, particularly in high-risk populations such as men who have sex with men and injecting drug users.
Rapid detection also helps get patients into effective care and treatment earlier.
Individuals who are unaware of their infection are 3.5 times more likely to transmit the virus to someone else.1
By detecting HIV earlier, further transmission can be prevented during this highly infectious stage.
The new Abbott™ Shiga Toxin Quik Chek™ assay is the only rapid test able to detect shiga toxin-producing E. Coli (STEC) toxins directly from fecal samples. The assay simultaneously detects and differentiates Stx1 and Stx2 toxins from STEC.
Easy to Use
The Abbott™ C. Diff Quik Chek Complete™ test is the only rapid cassette assay that simultaneously detects both glutamate dehydrogenase (GDH) antigen and toxins A & B of C. difficile in fecal specimens. The test detects C. difficile antigen, GDH, as a screen for the presence of C. difficile and confirms the presence of toxigenic C. difficile by detecting toxins A and B in fecal specimens from persons suspected of having C. difficile disease.
1. Williams, KM, Jackson MA, Hamilton M. (2002) Rapid Diagnostic Testing for URIs in Children: Impact on Physician Decision Making and Cost. Infect. Med. 19(3): 109-111.
2. Bonner, A.B. et al. (2003) Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric Emergency Department: Results of a Randomized, Prospective, Controlled Trial. Pediatrics. Vol. 112 No. 2.